Int J Biol Sci 2014; 10(2):142-148. doi:10.7150/ijbs.7727 This issue Cite
Review
1. Center for Translational Medicine, The First Affiliated Hospital of Xian Jiaotong University College of Medicine;
2. Department of Surgical Oncology, The First Affiliated Hospital of Xian Jiaotong University College of Medicine;
3. Department of Oncology, The First Affiliated Hospital of Xian Jiaotong University College of Medicine.
WWOX, a gene that spans the second most common chromosomal fragile site (FRA16D), often exhibits homozygous deletions and translocation breakpoints under multiple cellular stresses induced by extrinsic or intrinsic factors, such as hypoxia, UV, and DNA damage regents. Loss of WWOX is closely related to genomic instability, tumorigenesis, cancer progression and therapy resistance. WWOX heterozygous knockout mice show an increased incidence of spontaneous or induced tumors. WWOX can interact via the WW domain with proteins that possess proline PPxY motifs and is involved in a variety of cellular processes. Accumulating evidence has shown that WWOX that contains a short-chain dehydrogenase/reductase (SDR) domain is involved in steroid metabolism and bone development. Reduced or lost expression of WWOX will lead to development of metabolic disease. In this review, we focus on the roles of WWOX in metabolic disorders and tumors.
Keywords: WW domain-containing oxidoreductase, metabolic disorders, tumorigenesis, endocrine and chemotherapy.